BidaskClub Lowers Axovant Sciences (AXON) to Strong Sell
BidaskClub downgraded shares of Axovant Sciences (NASDAQ:AXON) from a sell rating to a strong sell rating in a report released on Wednesday morning.
A number of other equities research analysts have also recently weighed in on AXON. ValuEngine cut Axovant Sciences from a hold rating to a sell rating in a research note on Monday, June 11th. Zacks Investment Research cut Axovant Sciences from a strong-buy rating to a hold rating in a research note on Friday, June 15th. Oppenheimer reaffirmed a hold rating on shares of Axovant Sciences in a research note on Monday, July 9th. HC Wainwright reaffirmed a buy rating on shares of Axovant Sciences in a research note on Thursday, June 7th. Finally, Chardan Capital reaffirmed a hold rating and issued a $4.00 price objective on shares of Axovant Sciences in a research note on Wednesday, June 6th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the company. Axovant Sciences currently has a consensus rating of Hold and an average price target of $11.70.
Shares of NASDAQ AXON opened at $2.07 on Wednesday. Axovant Sciences has a twelve month low of $1.02 and a twelve month high of $27.98. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 1.48.
In related news, Director George Bickerstaff bought 25,000 shares of the stock in a transaction that occurred on Thursday, August 9th. The stock was purchased at an average cost of $2.07 per share, with a total value of $51,750.00. Following the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $103,500. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.00% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its stake in Axovant Sciences by 2,519.0% during the 1st quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 176,227 shares in the last quarter. BlackRock Inc. grew its stake in Axovant Sciences by 3.4% during the 1st quarter. BlackRock Inc. now owns 3,012,515 shares of the biotechnology company’s stock worth $4,006,000 after purchasing an additional 100,296 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in Axovant Sciences by 183.1% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 495,450 shares of the biotechnology company’s stock worth $1,120,000 after purchasing an additional 320,450 shares in the last quarter. A.R.T. Advisors LLC grew its stake in Axovant Sciences by 148.9% during the 1st quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 249,074 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Axovant Sciences by 175.6% during the 1st quarter. Millennium Management LLC now owns 1,330,910 shares of the biotechnology company’s stock worth $1,770,000 after purchasing an additional 847,946 shares in the last quarter. 9.38% of the stock is owned by hedge funds and other institutional investors.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Read More: Trading Strategy
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.